Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5-7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy.

@article{Markopoulos2005EffectOE,
  title={Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5-7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy.},
  author={Christos J. Markopoulos and M Chrissochou and A Michailidou and Evagelos Tzoracoleftherakis and Grigorios Xepapadakis and John Papadiamantis and John Misitzis and Vasilios Zobolas and Dimitrios I. Bafaloukos and Helen J. Gogas},
  journal={Anti-cancer drugs},
  year={2005},
  volume={16 8},
  pages={
          879-83
        }
}
Long-term endocrine therapy for breast cancer may have clinical implications as drugs that potentially alter the lipid profile may increase the risk of developing cardiovascular disease. In this study, a companion subprotocol to the ATENA (Adjuvant post-Tamoxifen Exemestane versus Nothing Applied) trial, we compared the effect of the steroidal aromatase inactivator exemestane on the lipid profile of post-menopausal women with operable breast cancer in the adjuvant setting to that of observation… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 15 CITATIONS

Similar Papers

Loading similar papers…